Livmarli
Total Payments
$4.1M
Transactions
4,632
Doctors
1,316
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.0M | 2,572 | 823 |
| 2023 | $2.0M | 1,620 | 627 |
| 2022 | $88,296 | 440 | 281 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2.4M | 461 | 57.7% |
| Consulting Fee | $1.3M | 441 | 30.6% |
| Travel and Lodging | $265,781 | 614 | 6.5% |
| Food and Beverage | $157,405 | 3,064 | 3.9% |
| Grant | $50,000 | 1 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,577 | 4 | 0.1% |
| Education | $736.26 | 42 | 0.0% |
| Entertainment | $373.86 | 4 | 0.0% |
| Compensation for serving as faculty or as a speaker for a medical education program | $350.00 | 1 | 0.0% |
Payments by Type
Research
$2.4M
461 transactions
General
$1.7M
4,171 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK) | Mirum Pharmaceuticals, Inc. | $730,430 | 0 |
| An Extension Study of Maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) (MARCH-ON) | Mirum Pharmaceuticals, Inc. | $404,675 | 0 |
| A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants with Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS) (RISE) | Mirum Pharmaceuticals, Inc. | $395,102 | 0 |
| A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects who Previously Participated in a Maralixibat Study (MERGE) | Mirum Pharmaceuticals, Inc. | $298,375 | 0 |
| A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) | Mirum Pharmaceuticals, Inc. | $242,128 | 0 |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients with Alagille Syndrome (LEAP) | Mirum Pharmaceuticals, Inc. | $172,406 | 0 |
| An Open-Label Study to Evaluate the Safety and Tolerability of Volixibat in Patients with Primary Biliary Cholangitis Currently Being Treated with Obeticholic Acid | Mirum Pharmaceuticals, Inc. | $80,191 | 0 |
| Evaluation of Maralixibat in Pruritus Associated with General Cholestatic Liver Disease (EXPAND) | Mirum Pharmaceuticals, Inc. | $31,000 | 0 |
Top Doctors Receiving Payments for Livmarli — Page 5
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Karie Robinson | Pediatrics | Liberty, MO | $786.03 | 4 |
| , MD | Pediatric Transplant Hepatology | New York, NY | $602.59 | 16 |
| , CPNP | Pediatrics | Bronx, NY | $570.39 | 7 |
| , MD | Gastroenterology | Memphis, TN | $525.51 | 3 |
| , ANP | Adult Health | Bethpage, NY | $481.57 | 2 |
| , MD | Pediatric Gastroenterology | Elmhurst, IL | $472.66 | 19 |
| James Squires | Pediatric Gastroenterology | Monroeville, PA | $453.80 | 8 |
| , CRNP | Pediatrics | Baltimore, MD | $426.48 | 3 |
| , M.D | Pediatrics | Madera, CA | $403.76 | 6 |
| , MD | Pediatric Gastroenterology | Bronx, NY | $401.32 | 12 |
| Ayesha Baig | Pediatric Gastroenterology | Madera, CA | $399.62 | 11 |
| , M.D | Pediatric Gastroenterology | Providence, RI | $398.76 | 11 |
| , PPCNP-BC | Pediatrics | Madera, CA | $386.50 | 10 |
| , MD | Pediatric Gastroenterology | Columbia, MO | $375.29 | 5 |
| , M.D | Pediatrics | St Louis, MO | $351.47 | 7 |
| , M.D | Pediatric Gastroenterology | New Haven, CT | $346.41 | 5 |
| , M.D | Pediatric Gastroenterology | Bronx, NY | $327.56 | 10 |
| , MD, MS | Pediatric Transplant Hepatology | New York, NY | $316.11 | 9 |
| Eric Dybbro | Pediatric Gastroenterology | Phoenix, AZ | $315.95 | 4 |
| , M.D | Pediatrics | Phoenix, AZ | $315.95 | 4 |
| , MD | Pediatric Gastroenterology | Las Vegas, NV | $315.43 | 9 |
| , MD | Pediatric Gastroenterology | Las Vegas, NV | $309.53 | 4 |
| , MD | Student in an Organized Health Care Education/Training Program | New York, NY | $305.73 | 3 |
| , M.D | Pediatric Gastroenterology | Spokane, WA | $301.28 | 4 |
| , M.D | Pediatric Gastroenterology | Spokane, WA | $301.28 | 4 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $4.1M
- Total Doctors 1,316
- Transactions 4,632
About Livmarli
Livmarli is a drug associated with $4.1M in payments to 1,316 healthcare providers, recorded across 4,632 transactions in the CMS Open Payments database. The primary manufacturer is Mirum Pharmaceuticals, Inc..
Payment data is available from 2022 to 2024. In 2024, $2.0M was paid across 2,572 transactions to 823 doctors.
The most common payment nature for Livmarli is "Unspecified" ($2.4M, 57.7% of total).
Livmarli is associated with 8 research studies, including "Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK)" ($730,430).